Efficacy of Puressentiel Protective Nasal Spray in Allergic Rhinitis (EPPNS)

Efficacy of Puressentiel Protective Nasal Spray on Symptoms and Inflammation in Patients With in Allergic Rhinitis

This study is a proof o concept aiming to determine the efficacy of Puressentiel nasal protective spray (PNPS) in patients with allergic rhinitis. Cross over study, with a nasal provocative test (NPT) in patients with allergic rhinitis sensitized to grass pollen. A day 0 (first NPT) the following outcomes are recorded: allergic Rhinitis control test (ARCT) and Inspiratory nasal peak flow (INPF) before and 30 min after the NPT. Nasal lavage is performed 30 min after the NPT and 3 cytokines (IL4, IL5 and IL13 are measured by ELISA. An other NPT is performed at day 30 and the same outcomes measured. 30 min before NPT 2 nasal sprays of PNPS are administered in each nostril in a randomized manner and cross over, the patient being is own control. The primary outcomes ins the IL4, IL5 and IL13 concentrations in the nasal lavage. ARCT and INPF are the secondary outcomes.

Inclusion Criteria: patients with diagnostic of allergic rhinitis sensitized to grass pollen for more than one year with or without associated asthma Exclusion Criteria: patients sensitized to a perrianual allergen patients with viral infection 4 weeks before inclusion patients with severe non controlled asthma patients with chronic sinusitis pregnancy or breast feeding patients with hypersensitivity to essential oil (eucalyptus radie) epileptic patient patients treated with nasal corticosteroid or anti-histamine